Association of hormone replacement therapy and carotid wall thickness in women with and without diabetes.

Dubuisson, J; Wagenknecht, Lynne E.; D'Agostino, R B; Haffner, S M; Rewers, Marian; Saad, Mohammad F.; Laws, Ami; Herrington, David M.

doi:10.2337/diacare.21.11.1790

Cited by 48 publications

(24 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…20 A reduced atherosclerosis measured by carotid wall thickness associated with HRT use in women with and without diabetes has been also reported. 22 Further investigations are required to evaluate if women with diabetes mellitus may receive the same benefit from HRT as women without diabetes.…”

Section: Discussionmentioning

confidence: 99%

Hormone Replacement Therapy and Incidence of Acute Myocardial Infarction

et al. 2000

View full text Add to dashboard Cite

Background-Epidemiological studies suggest a decreased risk of coronary heart disease (CHD) in healthy women taking hormonal replacement therapy (HRT). Whether this effect is shared by oral and transdermal preparations is unknown. Methods and Results-We conducted a population-based case-control study nested in a cohort of women 50 to 74 years of age without cardiovascular disease history in the United Kingdom. Among 164 769 women from the General Practice Research Database (January 1, 1991, to December 31, 1995), we identified 1242 first acute myocardial infarctions (AMI) and confirmed 1013 after medical record review. We randomly selected 5000 age-frequency-matched control subjects. AMI incidence was 1.6 per 1000 person-years; 13% and 17% of cases and control subjects used HRT within 6 months before the index date. Risk factor and comorbidity-adjusted OR of AMI for current-recent HRT users compared with nonusers was 0.72 (95% CI 0.59 to 0.89). The OR was similar within 30 days before the index date. The beneficial effect was present after 1 year of use (OR 0. 68; 95% CI 0.53 to 0.86), with no increase in risk within the first year. ORs for unopposed and opposed therapy were 0.52 (95% CI 0.35 to 0.78) and 0.79 (95% CI 0.59 to 1.08); 79% and 21% used oral and transdermal therapy. The protective effect was present at medium-high doses of estrogens with ORs for oral and transdermal therapy of 0.63 (95% CI 0.46 to 0.86) and 0.62 (95% CI 0.37 to 1.06) and ceased after 2 to 3 years since stopping HRT. Conclusions-Results are consistent with those previously reported in women without CHD who were taking oral HRT and, although based on few users, suggest that transdermal therapy might have similar cardioprotective effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Hormone Replacement Therapy and Incidence of Acute Myocardial Infarction

et al. 2000

View full text Add to dashboard Cite

show abstract

“…46 Similar beneficial effects were observed in healthy postmenopausal women with type 2 DM: treatment with either estrogen alone or with medroxyprogesterone improved glycemic control and lipid metabolism and decreased carotid wall thickness and atherosclerosis. [47][48][49][50][51] In addition, the selective estrogen receptor modulator raloxifene has been found to have favorable effects on concentrations of triglycerides and low-density lipoprotein in women with type 2 DM. 52 Based on these findings, HT appears to be beneficial in type 2 DM; however, very few studies to date have examined the effects of HT on diabetic end-organ complications, including diabetic nephropathy.…”

Section: Hormone Therapy and Diabetesmentioning

confidence: 99%

Estrogens and the diabetic kidney

Maric

Sullivan

2008

Gender Medicine

View full text Add to dashboard Cite

show abstract

“…È stata dimostrata una correlazione diretta tra IMT e rischio di infarto del miocardio e ictus in pazienti senza una storia di malattia vascolare [56], e diverse alterazioni metaboliche, come l'obesità [57], l'insulino-resistenza [58], l'iperandrogenismo [59], sono state largamente accettate come fattori di rischio per l'incremento dell'IMT.…”

Section: Struttura E Funzione Endoteliali Nella Pcosunclassified

The polycystic ovary syndrome: an example of obesity-related cardiovascular complication affecting young women

Orio

Cascella

Giallauria

et al. 2016

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

RASSEGNA IntroduzioneLa sindrome dell'ovaio policistico (PCOS) è una tra le più comuni patologie endocrine delle donne, essendone affetto il 5-10% delle donne in età riproduttiva [1,2].La PCOS è diagnosticata in presenza di due tra i tre criteri seguenti: 1. ovaie policistiche all'ecografia pelvica 2. oligo-anovulazione 3. evidenza clinica o biochimica di iperandrogenismo (Rottherdam ESHRE-ASRM 2003) [3]. La PCOS non è solo una delle cause principali di infertilità nelle donne, ma è considerata anche una vera e propria sindrome plurimetabolica [2,4,5]: obesità [6], insulino-resistenza [7], dislipidemia [8], alterazione del sistema fibrinolitico [9], sono le conseguenze metaboliche spesso evidenti in questa sindrome.Inoltre, la PCOS è associata a rischi per la salute a lungo termine, inclusi il diabete mellito [10] e la CDV (Malattia Cardiovascolare) [11][12][13][14][15].In particolare l'insulino-resistenza, l'iperandrogenismo e la dislipidemia sono probabilmente tra i maggiori fattori di rischio per l'incidenza della CDV nella PCOS. Tali fattori di rischio cardiovascolare sono spesso evidenti in giovane età, suggerendo che le donne con PCOS, rappresentano un numeroso gruppo di donne in cui è aumentato il rischio di sviluppo precoce di CDV, anche se ciò non è attualmente dimostrato [16].È stato riportato che il rischio di malattia coronarica e di infarto del miocardio è aumentato in pazienti con PCOS rispetto a donne con cicli regolari [11], anche se la mortalità dovuta a malattia circolatoria non sembra essere incrementata [17].Recenti studi hanno dimostrato un incremento della prevalenza di CDV in donne con PCOS [14][15][16][17]. Infatti nella PCOS è stata dimostrata disfunzione endoteliale [18) e diastolica [19] ed è stata associata sia ad elevati livelli di androgeni che ad insulino-resistenza.Di recente, insieme ai classici fattori di rischio CV, come i livelli di colesterolo totale e i livelli di lipoproteine ad alta densità per il colesterolo (HDL-C), l'obesità, l'omocisteina e l'ipertrofia ventricolare sinistra si sono dimostrati essere associati, indipendentemente, ad un incremento del rischio CV [20].

show abstract

Association of hormone replacement therapy and carotid wall thickness in women with and without diabetes.

Abstract: This analysis suggests that current and former use of HRT is associated with reduced atherosclerosis and that women with type 2 diabetes may receive the same benefit from HRI as women without diabetes.

Cited by 48 publications

References 14 publications

Hormone Replacement Therapy and Incidence of Acute Myocardial Infarction

Hormone Replacement Therapy and Incidence of Acute Myocardial Infarction

Estrogens and the diabetic kidney

The polycystic ovary syndrome: an example of obesity-related cardiovascular complication affecting young women

Contact Info

Product

Resources

About